Supriya Lifescience Ltd (SUPRIYA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003587, "name": "Supriya Lifesci.", "stock_name": "Supriya Lifesci.", "full_name": "Supriya Lifescience Ltd", "name_url": "stocks-analysis/supriya-lifesci", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "674.30", "chg": -10.45, "chgp": "-1.53%", "dir": -1, "prev_price": "684.75", "mcapval": "5,438.00 Cr", "mcap": "Small Cap", "scripcode": 543434, "symbol": "SUPRIYA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE07RO01027", "curr_date": "Feb 20", "curr_time": "", "bse_nse_vol": "53.57 k", "exc_status": "Active", "traded_date": "Feb 20, 2026", "traded_date_str": "2026 02 20", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/supriya-lifesci-1003587-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Supriya Lifescience Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-ltd-shows-mixed-technical-signals-amid-mildly-bullish-momentum-3846377", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_technicaldot_3846377.png", "date": "2026-02-19 08:03:57", "description": "Supriya Lifescience Ltd has recently exhibited a shift in price momentum, moving from a sideways trend to a mildly bullish stance, supported by a complex interplay of technical indicators. While some metrics signal optimism, others suggest caution, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "Supriya Lifescience Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-ltd-technical-momentum-shifts-amid-mixed-market-signals-3845145", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_technicaldot_3845145.png", "date": "2026-02-18 08:03:54", "description": "Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish trend to a sideways pattern. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, Bollinger Bands, and moving averages, which collectively paint a nuanced picture of the stock’s near-term prospects within the Pharmaceuticals & Biotechnology sector." }, { "title": "Supriya Lifescience Gains 1.84%: Mixed Technical Signals Shape Weekly Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-gains-184-mixed-technical-signals-shape-weekly-momentum-3838933", "imagepath": "", "date": "2026-02-14 10:04:00", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>9 Feb:</strong> Q2 FY26 results reveal strong sequential recovery despite margin pressure</p>\n <p><strong>9 Feb:</strong> Technical momentum shifts from mildly bullish to sideways trend</p>\n <p><strong>10 Feb:</strong> Technical momentum shifts again, now mildly bullish amid mixed signals</p>\n <p><strong>12 Feb:</strong> Stock gains 3.28% but technical indicators remain mixed</p>\n <p><strong>13 Feb:</strong> Week closes at Rs.681.25, up 1.84% vs Sensex decline</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</di..." }, { "title": "Supriya Lifescience Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/supriya-lifescience-ltd-is-rated-hold-by-marketsmojo-3834999", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_mojoScore_3834999.png", "date": "2026-02-12 10:10:03", "description": "Supriya Lifescience Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Supriya Lifescience Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-ltd-shows-mixed-technical-signals-amid-mildly-bullish-momentum-3834345", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_technicaldot_3834345.png", "date": "2026-02-12 08:05:11", "description": "Supriya Lifescience Ltd has recently shifted from a sideways technical trend to a mildly bullish stance, supported by a 3.28% gain in the latest trading session. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s performance relative to the Sensex and its evolving momentum suggest cautious optimism for investors in the Pharmaceuticals & Biotechnology sector." }, { "title": "Are Supriya Lifescience Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-supriya-lifescience-ltd-latest-results-good-or-bad-3831625", "imagepath": "", "date": "2026-02-10 19:39:46", "description": "Supriya Lifescience Ltd's latest financial results for Q2 FY26 indicate a notable recovery from previous quarters, with net profit reaching ₹50.43 crore, reflecting a significant sequential growth of 44.97%. Revenue also showed a robust sequential increase, rising to ₹199.83 crore, which is up 37.75% from the prior quarter. However, when compared year-on-year, revenue growth was more modest at 20.31%, and net profit increased by 9.27%. \n\nDespite these positive trends in revenue and profit, the company's operating margin has contracted to 36.35%, down from 38.96% in the same quarter last year, indicating ongoing pressures from input costs and competitive dynamics within the pharmaceutical sector. The decline in operating margin suggests that while the company is successfully expanding its top line, profitability is facing challenges.\n\nThe financial health of Supriya Lifescience remains strong, with a return ..." }, { "title": "Supriya Lifescience Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3829937", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_technicaldot_3829937.png", "date": "2026-02-10 08:07:11", "description": "Supriya Lifescience Ltd has recently exhibited a shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on daily moving averages, despite mixed signals from other key indicators. The stock’s current price of ₹685.80, up 2.52% from the previous close of ₹668.95, reflects cautious optimism among investors amid a challenging broader market environment." }, { "title": "Supriya Lifescience Q3 FY26: Modest Growth Amid Margin Pressures and Valuation Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/supriya-lifescience-q2-fy26-strong-sequential-recovery-masks-margin-pressure-3829405", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_quaterlyResult_3829405.png", "date": "2026-02-09 21:35:52", "description": "Supriya Lifescience Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹5,517 crores, reported a modest performance in Q3 FY26 (October-December 2025), posting a net profit of ₹49.68 crores, down 1.49% sequentially but up 6.20% year-on-year. The company's stock has declined 0.72% following the results announcement, trading at ₹680.00 as of February 13, 2026, reflecting investor concerns about margin compression and premium valuation despite steady revenue growth." }, { "title": "Supriya Lifescience Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/supriya-lifescience-ltd-technical-momentum-shifts-amid-mixed-market-signals-3827961", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SupriyaLifescie_technicaldot_3827961.png", "date": "2026-02-09 08:03:15", "description": "Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend as of early February 2026. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector." } ], "total": 283, "sid": "1003587", "stock_news_url": "https://www.marketsmojo.com/news/supriya-lifescience-1003587" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript", "datetime": "17-Feb-2026", "details": "Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31 2025 is enclosed herewith. Kindly take the same on record.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome", "datetime": "10-Feb-2026", "details": "Audio Recording of the Earnings Call for Unaudited Financial Results of quarter and nine months ended December 31 2025 is enclosed herewith.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "10-Feb-2026", "details": "Press Release for Unaudited Financial Results for quarter and nine months ended December 31 2025 is enclosed.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Supriya Lifescience Ltd has declared <strong>50%</strong> dividend, ex-date: 04 Sep 25", "dt": "2025-09-04", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

9 Feb: Q2 FY26 results reveal strong sequential recovery despite margin pressure

9 Feb: Technical momentum shifts from mildly bullish to sideways trend

10 Feb: Technical momentum shifts again, now mildly bullish amid mixed signals

12 Feb: Stock gains 3.28% but technical indicators remain mixed

13 Feb: Week closes at Rs.681.25, up 1.84% vs Sensex decline

Week OpenRead full news article

Supriya Lifescience Ltd is Rated Hold by MarketsMOJO

2026-02-12 10:10:03

Supriya Lifescience Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 20 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 February 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Supriya Lifescience Ltd Shows Mixed Technical Signals Amid Mildly Bullish Momentum

2026-02-12 08:05:11

Supriya Lifescience Ltd has recently shifted from a sideways technical trend to a mildly bullish stance, supported by a 3.28% gain in the latest trading session. Despite mixed signals from key technical indicators such as MACD, RSI, and moving averages, the stock’s performance relative to the Sensex and its evolving momentum suggest cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Supriya Lifescience Ltd latest results good or bad?

2026-02-10 19:39:46

Supriya Lifescience Ltd's latest financial results for Q2 FY26 indicate a notable recovery from previous quarters, with net profit reaching ₹50.43 crore, reflecting a significant sequential growth of 44.97%. Revenue also showed a robust sequential increase, rising to ₹199.83 crore, which is up 37.75% from the prior quarter. However, when compared year-on-year, revenue growth was more modest at 20.31%, and net profit increased by 9.27%. Despite these positive trends in revenue and profit, the company's operating margin has contracted to 36.35%, down from 38.96% in the same quarter last year, indicating ongoing pressures from input costs and competitive dynamics within the pharmaceutical sector. The decline in operating margin suggests that while the company is successfully expanding its top line, profitability is facing challenges. The financial health of Supriya Lifescience remains strong, with a return ...

Read full news article

Supriya Lifescience Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-02-10 08:07:11

Supriya Lifescience Ltd has recently exhibited a shift in its technical momentum, moving from a sideways trend to a mildly bullish stance on daily moving averages, despite mixed signals from other key indicators. The stock’s current price of ₹685.80, up 2.52% from the previous close of ₹668.95, reflects cautious optimism among investors amid a challenging broader market environment.

Read full news article

Supriya Lifescience Q3 FY26: Modest Growth Amid Margin Pressures and Valuation Concerns

2026-02-09 21:35:52

Supriya Lifescience Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹5,517 crores, reported a modest performance in Q3 FY26 (October-December 2025), posting a net profit of ₹49.68 crores, down 1.49% sequentially but up 6.20% year-on-year. The company's stock has declined 0.72% following the results announcement, trading at ₹680.00 as of February 13, 2026, reflecting investor concerns about margin compression and premium valuation despite steady revenue growth.

Read full news article

Supriya Lifescience Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-09 08:03:15

Supriya Lifescience Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish stance to a sideways trend as of early February 2026. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced outlook for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article